Jakavi Tablets

Ruxolitinib (as phosphate)
20mg
Novartis Pharma AG
Pack size 56's (14's Blister x 4)
Dispensing mode POM
Source SWITZERLAND
AgentCITY MEDICAL STORE
Retail Price 22805.50 AED

Indications

Jakavi Tablets is used for: Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-pv) myelofibrosis and post-essential thrombocythemia (post-et) myelofibrosis. [lexicomp] myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue)

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Ruxolitinib (as phosphate) :

Mechanism of Action

Ruxolitinib is a kinase inhibitor that is selective for the janus associated kinases (jak) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (stat) which modulate gene expression. Patients with myelofibrosis have abnormal jak1 and jak2 activity thus ruxolitinib works to regulate this

Note

Jakavi 20mg Tablets manufactured by Novartis Pharma AG. Its generic name is Ruxolitinib (as phosphate). Jakavi is availble in United Arab Emirates. Farmaco UAE drug index information on Jakavi Tablets is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Ruxolitinib (as phosphate) :